|
gptkbp:instanceOf
|
antidepressant
|
|
gptkbp:approvedBy
|
1969
|
|
gptkbp:ATCCode
|
gptkb:N06AA12
|
|
gptkbp:availableOn
|
gptkb:tablet
capsule
oral solution
topical cream
|
|
gptkbp:brand
|
gptkb:Adapin
gptkb:Silenor
gptkb:Sinequan
|
|
gptkbp:CASNumber
|
gptkb:1668-19-5
|
|
gptkbp:category
|
benzodiazepine
antidepressant
hypnotic
tricyclic compound
antipruritic
|
|
gptkbp:chemicalFormula
|
gptkb:C19H21NO
|
|
gptkbp:contraindication
|
urinary retention
narrow angle glaucoma
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:eliminationHalfLife
|
8-24 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Doxepin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
antihistamine
norepinephrine reuptake inhibitor
anticholinergic
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:prescribes
|
gptkb:generalized_anxiety_disorder
gptkb:major_depressive_disorder
chronic urticaria
sleep maintenance insomnia
|
|
gptkbp:proteinBinding
|
76%
|
|
gptkbp:PubChem_CID
|
3157
DB01142
|
|
gptkbp:routeOfAdministration
|
oral
topical
|
|
gptkbp:sideEffect
|
constipation
blurred vision
weight gain
drowsiness
dry mouth
urinary retention
|
|
gptkbp:synonym
|
3-dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropanamine
|
|
gptkbp:UNII
|
MN3L5RMN02
|
|
gptkbp:usedFor
|
gptkb:depression
anxiety
pruritus
insomnia
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|